July 2nd 2020, 7:10pm
Patient recruitment has been discontinued to an interim futility analysis of a phase 3 trial evaluating pracinostat in combination with azacitidine in patients with acute myeloid leukemia demonstrated that it is unlikely to meet the primary end point of overall survival compared with a control arm.
June 30th 2020, 11:05pm
Jia Ruan, MD, PhD, discusses the utility of molecular profiling in mantle cell lymphoma.
June 30th 2020, 8:21pm
A new drug application has been submitted to the FDA seeking an accelerated approval for melphalan flufenamide in combination with dexamethasone in the treatment of adult patients with triple-refractory multiple myeloma.
June 30th 2020, 3:33pm
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
June 30th 2020, 3:02pm
Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.
June 29th 2020, 7:35pm
Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.
June 29th 2020, 7:30pm
Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
June 29th 2020, 5:30pm
Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.
June 29th 2020, 2:04pm
Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.
June 26th 2020, 8:30pm
Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.
